EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022

Mariko Harada-Shiba, Akira Ohtake, Daisuke Sugiyama, Hayato Tada, Kazushige Dobashi, Kota Matsuki, Tetsuo Minamino, Shizuya Yamashita, Yukiyo Yamamoto

Journal of Atherosclerosis and Thrombosis · 01.05.2023 · 30 (5) · 531-557

DOI: 10.5551/jat.cr006 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.05.2023. Verfasst von Mariko Harada-Shiba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Osaka Medical and Pharmaceutical University. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, "probable FH" was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIAtherosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsHumansChildBlood Component RemovalGuidelines as TopicCholesterol, LDL

Stichwörter der Autor:innen

Diagnostic criteriaFamilial HypercholesterolemiaHeterozygoteHomozygoteLifestyleLow-density lipoprotein apheresisPediatricPharmacological therapyStatinsTreatment guidelines

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDL

Autor:innen und Institutionen

  • Cardiovascular Center, Osaka Medical and Pharmaceutical University.
  • Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
  • Department of Pediatrics, Faculty of Medicine, Saitama Medical University.
  • Faculty of Nursing and Medical Care, Keio University.
  • Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine.
  • Department of Pediatrics, School of Medicine, University of Yamanashi.

Zitieren

APA

Harada-Shiba, M., Ohtake, A., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., & Yamamoto, Y. (2023). Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis, 30(5), 531-557. https://doi.org/10.5551/jat.cr006

Vancouver

Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis. 2023;30(5):531-557. doi:10.5551/jat.cr006

BibTeX
@article{HaradaShiba2023,
  author = {Harada-Shiba, Mariko and Ohtake, Akira and Sugiyama, Daisuke and Tada, Hayato and Dobashi, Kazushige and Matsuki, Kota and Minamino, Tetsuo and Yamashita, Shizuya and Yamamoto, Yukiyo},
  title = {Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2023},
  volume = {30},
  number = {5},
  pages = {531--557},
  doi = {10.5551/jat.cr006}
}
Kostenlos starten →